|
|
|
For other announcements of interest to the medical community, choose a subcategory from the menu on the left.
|
|
|
|
|
|
Writing in the October 10th edition of the Journal of Clinical Oncology, IMF chairman Brian G.M. Durie, M.D., notes that 25 years ago only 48 percent to 66 percent of myeloma patients survived two years, depending on which treatment was used. By contrast today, two-year survival rates are around 90 percent. |
|
|
|
|
Dr. Durie says that the statistics from the VISTA trial leave no doubt that combination therapy with bortezomib is superior to MP alone. However, he raises the issue, "how does this clear-cut evidence inform treatment decisions?" |
|
|
|
|
Whether you are newly-diagnosed or well-versed in myeloma treatments, an IMF Patient & Family Seminar has something for you. If you are deciding whether to attend an IMF seminar, why not sit in on the Boston seminar held in July. The IMF cameras were there to capture it. |
|
|
|
|
The IMF Concise Review of the Disease and Treatment Options is an overview of myeloma, with a discussion of the pathophysiology, clinical features, and treatment options. It is hoped that the information will be helpful to health professionals and patients alike. |
|
|
|
|
Developed by the IMF's Nurse Leadership Board, these PDFs are part of the IMF Patient Education Tools Series and include preventing blood clots, managing steroid-associated side effects, managing myelosuppression, preventing peripheral neuropathy, and managing gastrointestinal side effects. |
|
|
|
|
|
The IMF Interviews
- Heinz Ludwig, MD
Wilhelminen Hospital, Vienna, Austria
- Roman Hájek, MD
Masaryk University, Brno, Czech Republic |
|
|
|
|
|
The IMF Interviews
- Antonio Palumbo, MD
University of Torino and the Italian Multiple Myeloma Study Group
- S. Vincent Rajkumar, M.D.
Associate Professor of Medicine, Mayo Clinic, Rochester, Minnesota |
|
|
|
|
Published in the Clinical Journal of Oncology Nursing, Volume 12, Supplement, June 2008, these guidelines are must-reads for all nurses—for all healthcare professionals—who are involved in the care of myeloma patients. |
|
|
|
|
A DNA bank that will provide genetic data research in new drug development. Read the latest update on this groundbreaking program. |
|
|
|
|
The International Myeloma Foundation is proud to sponsor the International Staging System (ISS). The ISS is a collaborative research initiative with nearly twenty myeloma institutions from around the world. |
|
|
print
back to top